A federal judge in Australia has put the kibosh on a half-million-dollar settlement over ill effects of Merck's ($MRK) painkiller Vioxx, a drug that has spawned billions of dollars in litigation.
Daktari Diagnostics reeled in another $7 million in equity financing, an amount likely to help fuel the company's overall expansion as well as the construction of a new plant in Scotland for its point-of-care-HIV tests.
Merck's U.K. group has raised its level of play in an industry-wide competition for the attention of physicians as they use the Internet.
What keeps Merck's security staff up at night? Animal rights activists and laid-off workers, apparently.
A year after HemCon Medical Technologies filed for Chapter 11 reorganization following the loss of a patent fight, the Oregon maker of gels and dressings has been sold.
Merck won the FDA's acceptance of a Biologics License Application for its investigational ragweed pollen allergy tablet to be delivered under the tongue.
Plaintiff Kelly Smith claimed Merck systematically discriminates against women and pregnant employees, even cutting the pay of managers whose subordinates take maternity leave.
GlaxoSmithKline and Merck are slashing the prices of their HPV vaccinations in a deal with the GAVI Alliance, which delivers immunizations to the developing world.
Social issues have held back uptake of GlaxoSmithKline and Merck human papillomavirus (HPV) vaccines in the U.S., but globally the problem is more fundamental--the shots cost too much. It is these low-income countries--where 85% of cervical cancer cases occur--that need the vaccines most though.
Merck & Co. hasn't spent huge amounts of time and resources pushing its consumer health business. While other Big Pharmas like Sanofi ($SNY) and GlaxoSmithKline ($GSK) went around the world snapping up smaller businesses in the space, Merck ($MRK) at first weighed the idea of selling off the consumer unit it acquired in its 2009 merger with Schering-Plough.